Joël Jean-Mairet
InvestorManaging Partner at Ysios Capital
Barcelona, Catalonia, Spain
Writes $1M – $7.5M checks · typically $1M
About
Joël Jean-Mairet is Managing Partner at Ysios Capital, where he oversees management, strategy and day-to-day operations. In 2001 he co-founded Glycart Biotechnology and served as its CEO until its sale to F. Hoffmann-La Roche four years later; Glycart originated the anti-CD20 antibody obinutuzumab/Gazyva. He holds an MSc in Biotechnology and a PhD in Cell Biology and Immunotherapeutics, both from ETH Zürich.
Contact· self-published, not guessed
Invests in
Biotech
Experience
- Ysios CapitalManaging Partner and co-Foundercurrent2007 — presentBarcelona
- ONA TherapeuticsDirectorcurrent2020 — presentBarcelona, Catalonia, Spain
- Inbiomotion S.L.Chairman of the Boardcurrent2012 — presentGreater Barcelona Metropolitan Area
- AM-PharmaBoard Observercurrent2019 — presentUtrecht, Netherlands
- AdcendoDirector2021 — 2024Copenhagen Municipality, Capital Region of Denmark, Denmark
- Mineralys Therapeutics, Inc.Board observer2022 — 2023
- Splice BioDirector2020 — 2023Barcelona, Catalonia, Spain
- Lava Therapeutics B.V. (NASDAQ: LAVA)Director2020 — 2022Utrecht, Netherlands
- Sanifit Laboratoris (now CSL)Director2015 — 2022
- Aura Biosciences (NASDAQ: AURA)Director2015 — 2021
- Rainier Therapeutics (now Fusion Pharmaceuticals - NASDAQ: FUSN)Director2017 — 2020San Francisco
- AM-Pharma B.V.Director2011 — 2019
- Medlumics S.L.Director2011 — 2017Madrid
- Dermalumics S.L.Director2014 — 2017Greater Madrid Metropolitan Area
- Tigenix N.V. (now Takeda Pharmaceuticals)Director2011 — 2013
- Biovex Inc (now Amgen)Board observer2009 — 2011
- Cellerix S.A. (now Takeda Pharmaceuticals)Chairman of the Board2007 — 2011Greater Madrid Metropolitan Area
- GLYCART Biotechnology AG (since 2005 Roche)CEO and co-founder2001 — 2006
Skills & more
Biotechnology65Drug Discovery13Due Diligence9Entrepreneurship23Mergers2Oncology8Start-ups37Strategy17Technology Transfer32Venture Capital75Venture Financing7Restructuring2
+12 more
RBiopharmaceuticalsBusiness StrategyClinical DevelopmentCommercializationCorporate DevelopmentCorporate FinanceDrug DevelopmentFDAInnovation ManagementInvestmentsLicensingFrom Joël's professional profile.
Investments
Board seats
AdcendoAM-PharmaAura BiosciencesInbiomotionLAVA TherapeuticsMedLumicsOna TherapeuticsSanifit TherapeuticsSplice Bio
Per the firm's website.
Colleagues at Ysios Capital
Almudena Méndez
Associate at Ysios Capital
Antoni Ribas
Venture Partner at Ysios Capital
Arturo Urrios
Partner at Ysios Capital
Carlos Garcia-Echeverria
Venture Partner at Ysios Capital
Carlos Paya
Venture Partner at Ysios Capital
Catalina Cuchy
Executive Assistant at Ysios Capital
Cristina Garmendia
General Partner at Ysios Capital
David L. Lacey
Venture Partner at Ysios Capital
Network1
Investors connected to Joël in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Joël Jean-Mairet?
- Joël Jean-Mairet is Managing Partner at Ysios Capital, where he oversees management, strategy and day-to-day operations. In 2001 he co-founded Glycart Biotechnology and served as its CEO until its sale to F. Hoffmann-La Roche four years later; Glycart originated the anti-CD20 antibody obinutuzumab/Gazyva. He holds an MSc in Biotechnology and a PhD in Cell Biology and Immunotherapeutics, both from ETH Zürich.
- Where does Joël Jean-Mairet work?
- Joël Jean-Mairet is Managing Partner at Ysios Capital.
- What does Joël Jean-Mairet invest in?
- Joël Jean-Mairet invests in Biotech.
- What check size does Joël Jean-Mairet write?
- Joël Jean-Mairet typically writes checks of $1M – $7.5M.
- What boards does Joël Jean-Mairet sit on?
- Joël Jean-Mairet holds tracked board seats at Adcendo, AM-Pharma, Aura Biosciences, Inbiomotion, LAVA Therapeutics, MedLumics, Ona Therapeutics, Sanifit Therapeutics, Splice Bio.
- Where did Joël Jean-Mairet go to school?
- Joël Jean-Mairet studied at Eidgenössische Technische Hochschule Zürich (PhD, MSc, Biotechnology, Cell Biology, Therapeutic Antibodies).
Same school
Also attended Eidgenössische Technische Hochschule Zürich246
Bastian HasslingerInvestor at Index VenturesKJ SidberryInvestor at GV (Google Ventures)Steve VassalloInvestor at Foundation CapitalHelge DaebelPartner, Head of Water at Emerald Technology Ventures AgMaurin DaiInvestment Manager, Physical AI & Robotics at Emerald Technology Ventures AgChristoph FreiPartner, Head of Energy at Emerald Technology Ventures Ag
+ 240 more
Shared employers
Also worked at ONA Therapeutics8
Clara CampàsCo-founder and managing partner at Asabys PartnersGuillem MasferrerPartner at Asabys PartnersMontse VendrellPartner at Asabys PartnersPamela KleinVenture Partner at Ysios CapitalJonathan DupontAssociate at Mérieux Equity PartnersThomas MackiolInvestment Manager at CFH Management GmbH
+ 2 more
